[
    {
        "utterance": "Faranak Fattahi: third point stem cells of the peripheral nervous system, particularly the enteric nervous system, and we're interested in figuring out how these different enteric neurons and glia within these organoids are affected in disease. So in the gut those would be motility diseases that you know, lead to abnormalities in movement of the gut tube and the muscle tissue. We're also interested in figuring out how neurological diseases like Parkinson's and Alzheimer's and other neurodegenerative diseases manifest in the enteric nervous system. So, this is a brief overview. ",
        "annotations": {
            "develop idea": "The speaker is expanding on their research interest, providing specific examples of diseases and their relevance to the enteric nervous system.",
            "clarify goal": "The speaker is defining, clarifying the objectives and area of investigation by outlining the research focus on stem cells of the peripheral nervous system and disease implications."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. That was that was great. Erin. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input.",
            "supportive response": "The speaker expresses a positive evaluation for the contribution."
        }
    },
    {
        "utterance": "Erin Longbrake: Hi, I'm Erin Longbrake. I'm at Yale. I'm a neuroimmunologist. My research is mainly in multiple sclerosis, um, and I'm interested in detecting the disease before it has caused damage to the nervous system. So I'm interested in the microbiome both as something that might facilitate some of the genetic environmental interactions that lead to the immune disregulation of MS. I'm also interested in in it as a biomarker of something that may be able to help us detect um, when something first starts to go awry that ultimately would lead to autoimmunity. Um, so that's my general interests. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task, such as being a neuroimmunologist and her research focus on multiple sclerosis."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. Thank you. Pamela. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive evaluation with 'That's great'.",
            "encourage participation": "The speaker is inviting Pamela to contribute or share her thoughts."
        }
    },
    {
        "utterance": "Pamela Chang: Hi, my name is Pamela Chang and I'm an assistant professor at Cornell in Ithaca. Um, my lab is interested in developing chemical tools to characterize or study the metabolism of the gut microbiome. And we also look at small molecule metabolites that bacteria in the gut make and how that modulates host immune responses in inflammatory diseases and also in an infection. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is primarily an introduction."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. Thank you. ",
        "annotations": {
            "acknowledge contribution": "Rosa Krajmalnik-Brown verbally recognizes Pamela Chang's input.",
            "supportive response": "Rosa Krajmalnik-Brown expresses a positive evaluation for Pamela's contribution."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Um, uh Leon? Ilian? ",
        "annotations": {
            "encourage participation": "The speaker is inviting someone to contribute by calling their name, indicating an attempt to encourage participation in the conversation."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: How do you pronounce your name? How do you say your name? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on how to pronounce Iliyan Iliev's name."
        }
    },
    {
        "utterance": "Iliyan Iliev: Ilian. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Ilian. Okay, sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Hi, so uh I'm a associate professor in Wild Cornell Medicine, which is the medical campus of Cornell University here in uh New York City. Uh my lab is immunology lab, but we are very interested in the microbiota and more specifically in the fungal microbiota. Uh so in the area of uh of neuroimmunology that came in the lab with the observation that uh specific fungi and their metabolites can actually ramp up a signaling which turned out to be through a cytokine called L17 uh and uh the receptors expressed in neurons and that modulates behavior. So that's some uh direction that we are pursuing right now. And we are looking in patients populations how that is working and how polymorphisms and loss of function mutations are affecting those phenotypes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his position as an associate professor and mentions his lab's focus, indicating his expertise.",
            "develop idea": "The speaker is elaborating on his lab's research interests and specific areas of focus within immunology and neuroimmunology."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. We're looking at fungi also on our new treatment. So, um Oh nice. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Iliyan Iliev's research introduction with 'That's great.'",
            "develop idea": "The speaker shares their own related research, 'We're looking at fungi also on our new treatment.'",
            "express humor": "The speaker ends with a positive, possibly humorous tone, 'So, um Oh nice.'"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, we we just had like one study that came up and we are following up on that. So it's kind of very interesting. ",
        "annotations": {
            "express humor": "The speaker makes a joke or a lighthearted comment."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Again, so I'm happy to talk about that later if you want. All right, great. Um, so Tom. ",
        "annotations": {
            "encourage participation": "The speaker invites Tom to participate by saying 'Um, so Tom.'",
            "process management": "The speaker manages the conversation flow by transitioning to another topic or person."
        }
    },
    {
        "utterance": "Tom Mansell: Hi, Tom Mansell. I am in uh chemical and biological engineering at Iowa State University. Our interest is in the microbiome as an ecosystem where uh that's that's going to be harsh to our bug of interest, which is a live biotherapeutic. So our goal is to secrete small molecules or peptides or proteins in situ in the gut and in order to do that, obviously it has to thrive in this very competitive environment and be able to do its job, which is secretion of the of the therapeutic. And so we're really interested in we do genome engineering to look at the genes that affect survival phenotypes of these bacteria and we're also interested in the um access between prebiotics uh and uh and the growth of these bugs in this environment. So we're really interested in engineered uh synbiotics where we take prebiotics and mix them with probiotics and uh improve their overall outcomes. ",
        "annotations": {
            "propose new idea": "The speaker introduces new information about his research focus on the microbiome, live biotherapeutics, and engineered synbiotics.",
            "develop idea": "The speaker elaborates on his research interests, providing specific details about goals and methods.",
            "signal expertise": "The speaker mentions his position in chemical and biological engineering at Iowa State University."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. Uh, Melanie. ",
        "annotations": {
            "encourage participation": "The speaker invites Melanie to contribute, indicating a desire for her participation or input.",
            "acknowledge contribution": "The speaker thanks someone, acknowledging a contribution or statement made prior to their utterance."
        }
    },
    {
        "utterance": "Melanie Gareau: Um, I'm Melanie Gareau. I'm an associate professor at the Vet school at UC Davis. Um, and my lab's interested in looking at the development of the microbiota gut brain axis, so how colonization impacts maturation of the gut and how that's reflected in changes in our development and behavior in adulthood. Um, I'm a GI physiologist by training and uh we're really interested how this connects with um pediatric IBD and overall IBD in adulthood. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their position and background, indicating their expertise.",
            "develop idea": "The speaker is elaborating on their research focus, providing details about their work."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. So I put the question in the, I don't know if you guys see the in the chat. I put the topic for our conversation. But before we start taking the conversation, I need someone to volunteer to be a scribe. ",
        "annotations": {
            "process management": "The speaker is managing meeting flow by seeking a volunteer to act as a scribe for the conversation."
        }
    },
    {
        "utterance": "Erin Longbrake: I can do it. Um where are we supposed to type notes though? Was there a Google document somewhere or ",
        "annotations": {
            "process management": "Erin is asking about the process of note-taking, specifically where to type notes.",
            "ask question": "Erin is seeking information about where to type notes and if there is a Google document for note-taking."
        }
    },
    {
        "utterance": "Andrew Feig: There is a word doc that if you go into the Google Drive, do you have are you in the Google Drive? I'm in the Google Drive, yeah. Uh go into the virtual meeting materials. Yep. The the ultimate PowerPoint slide is at the very bottom. Syllog MD 2022 meeting slides. Yeah. And then there's a raw notes from breakout sessions folder. If you go in there, each breakout session has a raw notes that you you can just freehand just uh ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by providing instructions on how to access and use documents for note-taking."
        }
    },
    {
        "utterance": "Erin Longbrake: We're 1.4. ",
        "annotations": {
            "process management": "This code might seem applicable as it relates to the organization or status within the meeting or task, though it's quite minimal."
        }
    },
    {
        "utterance": "Andrew Feig: Yep. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Okay, thanks. All right, I'm I'm good. ",
        "annotations": {
            "Acknowledge contribution": "Erin is verbally recognizing Andrew's input and help.",
            "Supportive response": "Erin is expressing a positive response to Andrew's instructions."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Barriers affecting the gut brain axis. That's the topic. And I just put on the comments box um the description of our breakout session and I can maybe start with um asking questions and see who wants to start answering. So are permeability changes linked or correlated to um the gut brain axis and yeah, the the blood brain barrier and the intestinal barrier and the mucocil barrier um and how they're altered during um disease states. Hold on one second, I need to close my door. ",
        "annotations": {
            "ask question": "The speaker requests information about the relationship between permeability changes and their correlation with various barriers in disease states.",
            "encourage participation": "The speaker invites group members to contribute by answering the posed question."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I apologize for that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: All right, Erin, are you ready? ",
        "annotations": {
            "encourage participation": "The speaker is inviting Erin to contribute or confirm her readiness to participate in the discussion."
        }
    },
    {
        "utterance": "Erin Longbrake: Yep, I'm I'm good. ",
        "annotations": {
            "Supportive response": "The speaker confirms they are ready to proceed, which is a positive and cooperative reaction."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So we have great expertise in this panel because we have people that are focused on um the chemicals, organoids, the gut, the brain, immunology, so um I I expect great discussion about this. So who wants to get started? ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute with the question 'So who wants to get started?'",
            "process management": "The speaker is managing the meeting flow by inviting others to participate and start the discussion.",
            "supportive response": "The speaker expresses a positive sentiment towards the discussion, indicating they expect a 'great discussion'."
        }
    },
    {
        "utterance": "Faranak Fattahi: So I can maybe like start. Um, you know, thinking about the enteric nervous system, um, and how the neurons in the gut regulate the tissue homeostasis. I know they play an important role in uh the the epithelial barrier. And so if you have inflammatory conditions that affect the neurons or in some uh developmental defects if the nerves are not developed properly or the tissues as they call it aganglionic, the epithelium becomes leaky then that then leads to more inflammation and more damage to the nerves and this cascade this perpetual cascade of tissue inflammation and breakdown. ",
        "annotations": {
            "develop idea": "The speaker elaborates on the enteric nervous system's role in regulating tissue homeostasis and its impact, providing a more detailed explanation."
        }
    },
    {
        "utterance": "Iliyan Iliev: So so in humans, there are direct uh correlations. So we went after some of those genetically, right? So you go actually and you target pathways that are involved in uh in tight junction and uh in uh pathways that are indirectly actually uh correlated to barriers. And that and then if you have actually microbial trigger, you can affect directly the uh blood brain barrier. So uh the question now is uh so so once you come up uh come up with a driver and then a trigger, the question is like uh to what extent it's uh it's really affected and then uh if that will leave lead to uh any physiology. So that's something that we are trying to explore and like how big is that uh change and you can go with different particles and so on, you can figure out uh what size molecules can actually get into the brain, right? Which is important as well. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by discussing pathways involved in tight junctions and their correlation to barriers, and how microbial triggers can affect the blood-brain barrier.",
            "ask question": "The speaker asks questions about the extent of the effect of microbial triggers on the blood-brain barrier and its impact on physiology."
        }
    },
    {
        "utterance": "Jilyan Iliev, WCM, Cornell University: working that area and to kind of follow up. Uh, so if you guys because we are very new, you know, I worked a lot on the gut barrier but not the blood brain barrier. So we are applying a lot of knowledge like that, but uh, I'm not sure what is the best literature. I I did a lot of research on that but couldn't really find the best one that will address the question about how big molecules can go depending on your genetic defect. ",
        "annotations": {
            "identify gap": "The speaker recognizes a lack of knowledge regarding specific literature on the blood-brain barrier and genetic defects.",
            "ask question": "The speaker requests information on how big molecules can pass depending on genetic defects."
        }
    },
    {
        "utterance": "Erin Longbrake (Yale): Would the molecule need to be appropriately sized though? I mean, in a sense, if you have inflammatory mediators that are within the bloodstream, they could impact the endothelium and create leakiness that would be independent of the size of the molecule because once you've broken down the barrier then large molecules can pass too. ",
        "annotations": {
            "ask question": "Erin is asking a question about the necessity of a molecule being appropriately sized to affect the barrier.",
            "develop idea": "She is expanding on existing ideas by providing a perspective on how inflammatory mediators could affect the barrier."
        }
    },
    {
        "utterance": "Jilyan Iliev, WCM, Cornell University: They can, but then uh, the other question is uh, you know, some of those uh, susceptibilities or those uh, defects in the barrier you cannot uh, really uncover until you have the proper trigger. So sometimes the trigger is not known. So you have to actually really come up with a system where you predict triggers because if you do it genetically in different mouse models that can be huge in their price, right? You it's not a lab, it's kind of a company that has to do it. But if you can predict, then you can then go by size because some of those things will be not specific but others will be. So I don't know, that's my thinking there but uh. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing challenges and potential approaches to studying susceptibilities or defects in barriers."
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: Are there in vitro models that are more scalable for screening through uh molecules that are permeable or unpermeable through the blood brain barrier? Or you know how pharma companies used to like test drug permeability, so some of those might be useful for microbial metabolites as well. I'm not sure if any screens in this uh realm has been done before or the models good enough for these types of studies. ",
        "annotations": {
            "ask question": "The speaker is explicitly requesting information about the existence of in vitro models for screening molecules through the blood-brain barrier and their potential application.",
            "identify gap": "The speaker expresses uncertainty about whether screens in this realm have been done before or if the models are good enough for these types of studies, indicating a recognition of a gap in knowledge."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): So Pamela, you work with metabolites and with small molecules. Um, any any thoughts about this? ",
        "annotations": {
            "ask question": "The speaker is requesting information or thoughts from Pamela on a specific topic.",
            "encourage participation": "The speaker is inviting Pamela to contribute her expertise or opinions."
        }
    },
    {
        "utterance": "Pamela Chang, Cornell: Yeah, so we, I mean in the gut, we look at barrier with uh, uh, you know, either ticker two cells that can form a monolayer and then you can give the trigger and then measure flux with fluorescent molecules of different sizes, but I'm actually not familiar with the blood brain barrier either. ",
        "annotations": {
            "develop idea": "The speaker is sharing her approach to studying barriers in the gut, providing a concrete example of her work.",
            "identify gap": "The speaker explicitly states her lack of familiarity with the blood-brain barrier, recognizing a gap in her expertise."
        }
    },
    {
        "utterance": "Pamela Chang, Cornell: Iyan? ",
        "annotations": {
            "encourage participation": "The utterance 'Pamela Chang, Cornell: Iyan? ' is an invitation for Iyan to contribute to the conversation, fitting the definition of encouraging participation."
        }
    },
    {
        "utterance": "Jilyan Iliev, WCM, Cornell University: Uh, well the the problem is that you have if you do it through the gut brain axis, you have the intestinal barrier and then the blood brain barrier. So it's very hard to model both in an in vitro system. That's why we went for the in vivo system. So we want to see if a defect in one or two is happening and so on. So that's how we couldn't that's why if there is a system to do that in vitro that will be fantastic. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the challenges of modeling the gut-brain axis, specifically the intestinal barrier and the blood-brain barrier, building upon the previous conversation.",
            "identify gap": "The speaker is highlighting the gap in current research, specifically the difficulty in modeling the barriers in vitro."
        }
    },
    {
        "utterance": "Andrew Feig (RCSA (he/him)): There's actually an interesting system involving focused ultrasound that you can use to temporarily change the brain uh the CNS barriers. Uh so the blood brain barrier where you can uh the focused ultrasound will cause a temporal gap in the blood brain barrier that allows passage over the span of say 30 seconds and then you can close it again. And so so that would allow you to at least isolate that barrier separate from the intestinal barrier. Um, just a thought. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new method (focused ultrasound) for temporarily altering the blood-brain barrier.",
            "offer feedback": "The speaker provides a suggestion that could be useful for further consideration regarding isolating the blood-brain barrier from the intestinal barrier."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): So on the intestinal barrier, I'm trying not to talk too much, but I'm just going to mention quickly that the the the paper that I mentioned by Sarkis Mazmanian group Cell 2013, one of the things that they show is that they show that the the the gastrointestinal barrier was uh damage in these mice that had autism like behaviors and that they could repair it with bacterio fragilis. They show that with images of the tissue. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the existing discussion by introducing and elaborating on a specific study to provide evidence related to the intestinal barrier and its implications."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Faranak? ",
        "annotations": {
            "encourage participation": "The speaker is inviting Faranak to contribute their thoughts or ideas to the discussion."
        }
    },
    {
        "utterance": "Faranak Fattahi, UCSF: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Yeah. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement, validation, or positive evaluation for other group members' contributions without adding new content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): And. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Yeah. ",
        "annotations": {
            "Supportive response": "The utterance 'Yeah.' expresses agreement or acknowledgment with what was previously said, fitting the definition of a supportive response."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown (ASU): Yeah. ",
        "annotations": {
            "supportive response": "The utterance 'Yeah.' is a simple acknowledgment that agrees with or validates a previous statement."
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): Yeah. ",
        "annotations": {
            "Supportive Response": "The utterance 'Yeah.' is an expression of agreement, making it a supportive response to the previous statement."
        }
    },
    {
        "utterance": "Melanie Gareau (UC Davis): So if I can go back to the metabolites, I know that we we use using chambers to study intestinal physiology, so we can look at ion transport and permeability in pretty good detail. And if you provide certain fatty acids for example, you can improve a disrupted barrier. So metabolites can play a role. Um, with respect to the correlation versus associations, the best one that I know of is IBD where you can measure permeability defects in patients before they become IBD patients if you do a screen. So it suggests that permeability is one of the initiating factors. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of metabolites' role in intestinal physiology and barrier function, providing examples and evidence.",
            "offer feedback": "The speaker provides specific examples and study findings to support the discussion on metabolites and intestinal barrier function, which can be seen as offering feedback or insights."
        }
    },
    {
        "utterance": "Tom Mansell: and the host aspect is is is not my area of expertise, but I do know that there are biotics that if you when administered, they do create better tight junctions, right? So E coli is an example of uh of a probiotic that um one of its functions of course is to is is niche defense because it's very similar to Shigella and uh salmonella, but um uh another thing that that's been found is in in these kind of monolayer type studies, I not I don't know about in vivo right now, but um you you find increased tight junction formation just from the administration of this this E coli. Um and so the ",
        "annotations": {
            "develop idea": "Tom is expanding on the idea of how biotics can affect tight junctions, using E coli as an example.",
            "offer feedback": "Tom is providing specific information about E coli and its effects, which can be seen as offering feedback.",
            "signal expertise": "Tom explicitly states that the host aspect is not his area of expertise, which can be seen as signaling his limitations in expertise."
        }
    },
    {
        "utterance": "Tom Mansell: what is the host? So there's, you know, we monitor these things with what E cadherin uh and and other gene expression, right? So um but the actual barrier between cells is uh a sort of mostly protein, mostly extracellular matrix type material, like what is the downstream effect? Like what what we're talking about so far is like what signaling leads to this phenotype, right? But is it is there something about like um the the protein or carbohydrate makeup or availability of those things that may um that may contribute to that and you know, that's that's just I I think about things a lot on the molecular level. So that's that's kind of where I'm sort of coming from here and so if anybody can enlighten me in that respect that would be great. ",
        "annotations": {
            "ask question": "The utterance explicitly requests information and clarification.",
            "develop idea": "Tom Mansell is expanding on previous discussions by asking for more details.",
            "identify gap": "The speaker implies a gap in his understanding, asking for clarification."
        }
    },
    {
        "utterance": "Faranak Fattahi: are you thinking that some of those components could be affected by the microbiome as well? Like could be directly secreted by them or expressed proteins and the host could be altered by factors from the microbiome? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on how the microbiome could affect the host's cellular components.",
            "develop idea": "The speaker is expanding on a previous topic by asking a question that seeks further clarification."
        }
    },
    {
        "utterance": "Tom Mansell: Right, so that could be a possible explanation for why short chain fatty acids would do that for example, right? Um as histone deacetylase uh inhibitors. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea by suggesting a possible explanation for how short chain fatty acids work.",
            "offer feedback": "The speaker provides a specific suggestion for understanding how short chain fatty acids work, which can be seen as a form of feedback."
        }
    },
    {
        "utterance": "Tom Mansell: Um but yeah, I'm I'm really thinking more about the physical makeup of the barrier and is there a you know a nutrient linked um is there something there that's nutrient linked for a bacterium is providing or taking away um an essential building block of of the barrier. ",
        "annotations": {
            "Ask question": "Tom is asking a question about potential mechanisms by which bacteria could affect the barrier, specifically regarding nutrient links and essential building blocks.",
            "Develop idea": "Tom is expanding on the idea of how the microbiome interacts with the host's barrier, specifically focusing on the physical makeup and potential nutrient links."
        }
    },
    {
        "utterance": "Tom Mansell: Any ",
        "annotations": {
            "ask question": "Tom Mansell is seeking information or clarification."
        }
    },
    {
        "utterance": "Tom Mansell: Any ",
        "annotations": {
            "ask question": "The speaker is seeking information or agreement from others, indicated by 'Any'.",
            "encourage participation": "The speaker is inviting others to contribute their thoughts or ideas."
        }
    },
    {
        "utterance": "Tom Mansell: Any thoughts on that or there particular ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification from other team members on a prior statement or idea.",
            "encourage participation": "The speaker is inviting others to contribute their expertise or opinions."
        }
    },
    {
        "utterance": "Erin Longbrake: Any ",
        "annotations": {
            "ask question": "The speaker is attempting to ask a question or seek information, although the question is not fully articulated."
        }
    },
    {
        "utterance": "Iliyan Iliev: Any ",
        "annotations": {
            "None": "No relevant code fully applies to this incomplete utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: And it's probably worth also thinking that sorry, sorry, were you Erin, were you ",
        "annotations": {
            "ask question": "The speaker is seeking clarification or confirmation from Erin.",
            "encourage participation": "The speaker is directly engaging Erin in the discussion."
        }
    },
    {
        "utterance": "Erin Longbrake: I was just going to say that something that seems like could be a question that could be studied in an in vitro model system. I don't know the answer though, but it seems like a question that would be amenable to in vitro studies. ",
        "annotations": {
            "develop idea": "The speaker is suggesting a method (in vitro model system) for studying the question at hand.",
            "identify gap": "The speaker mentions not knowing the answer, indicating a gap in their knowledge.",
            "offer feedback": "The speaker provides a suggestion for how to proceed with studying the question."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, the internet kicked me out and it took me a while to be able to get back in. So I hope you guys were doing great without your moderator. ",
        "annotations": {
            "Process management": "The speaker is managing the meeting flow by addressing her temporary absence and expressing hope that the discussion proceeded well."
        }
    },
    {
        "utterance": "Faranak Fattahi: Just me talking, so no. ",
        "annotations": {
            "None": "No relevant code explicitly applies to this utterance, but it could be argued to have a minimal supportive tone."
        }
    },
    {
        "utterance": "Iliyan Iliev: Oh ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: taking notes. So I we should let give her a chance to talk also because I know she's been busy taking notes. ",
        "annotations": {
            "process management": "The speaker is managing the conversation flow, ensuring that note-taker has a chance to contribute.",
            "encourage participation": "The speaker is inviting someone who has been busy taking notes to participate in the discussion."
        }
    },
    {
        "utterance": "Tom Mansell: Dave, I think you were going to say something there. ",
        "annotations": {
            "encourage participation": "Tom Mansell is inviting Dave to contribute to the conversation by suggesting he had something to say."
        }
    },
    {
        "utterance": "Dave Durgan: Sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dave Durgan: Oh, I was just going to bring up a more direct interaction, not necessarily metabolites, but active things like proteases like ginger pains and things that can uh at least from the oral bacteria uh have been shown to both break down the epithelium as well as the endothelial barrier uh in brain um so that's more of a a direct protease route which has been shown to have effects at both sites. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about the role of proteases from oral bacteria in affecting the gut-brain axis, specifically through the breakdown of epithelium and endothelial barriers.",
            "offer feedback": "The speaker provides a new perspective by suggesting a direct protease route as a mechanism through which the microbiome could influence the brain, which can be seen as offering feedback on the discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So in the gut um um, I don't know if you looked at proteases and fungi because that might be important also. ",
        "annotations": {
            "ask question": "The speaker is explicitly seeking information on whether proteases and fungi have been considered in the discussion.",
            "propose new idea": "The speaker introduces proteases and fungi as potentially important factors to consider in the context of the gut-brain axis."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, we do, we do. We actually have few candidates that that we discovered with uh yeah, human uh human uh antibody assays. ",
        "annotations": {
            "signal expertise": "The speaker is explicitly stating his team's capabilities and findings related to discovering candidates using human antibody assays."
        }
    },
    {
        "utterance": "Iliyan Iliev: Uh and they they are few proteases that are uh you know, that are involved but uh I'm not sure at what level because there are two ways how the barrier, at least two ways, right? How the barrier might be impaired. It can be directly through, you know, tight junction defects and then uh you know, external factors that are uh that are basically aggravating those phenotypes. But then the other problem is actually reparative problems. So those are like very long term uh you know, processes and they can be taking part in specific areas of the intestine. So it's different from the cellular and both of those have have similar effect of uh increased permeability. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing mechanisms of barrier impairment and reparative problems."
        }
    },
    {
        "utterance": "Iliyan Iliev: So so so that's how it's very complicated, right? There there is so much uh to do on that side but uh but you know, those two different levels of complication a bit mess up uh the screening approaches because if you start looking at tight junctions, you can set up an in vitro platform and do some part of that with the caveat you don't have immune system there which is very important for this process of basically bringing uh the tight junctions. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the challenges of studying tight junctions and the limitations of in vitro platforms.",
            "identify gap": "The speaker identifies a gap in current methods (the inability to fully study the process in an in vitro platform due to the lack of an immune system).",
            "offer feedback": "The speaker is providing specific commentary on the challenges and limitations of a particular approach."
        }
    },
    {
        "utterance": "Iliyan Iliev: That's a good point though. Um so it sounds ",
        "annotations": {
            "supportive response": "The speaker expresses agreement or validation with 'That's a good point though.'"
        }
    },
    {
        "utterance": "Erin Longbrake: That's a good point though. Um so it sounds going back to the original question, it sounds plausible that certain microbes um either make small metabolites that impact the barrier or make proteases that impact components of the barrier. But certainly microbes also impact immune cells which are in the mucosal layers and certainly immune cells have a number of ways to bypass barriers um to migrate into both the brain and other parts of the body to make active metabolites and so you know that one question could be whether the it's a direct effect of um microbes and microbial products or whether the immune cells serve as a as a mediator. ",
        "annotations": {
            "develop idea": "The speaker is expanding, building upon, or elaborating existing ideas through reasoning and examples."
        }
    },
    {
        "utterance": "Iliyan Iliev: And there is one more component actually, toxins. So we just had a study uh there is a fungal toxin that is basically directly uh uh lytic to epithelial cells and microphages underneath. Uh and that is messing up the system a lot and that's not a protease. ",
        "annotations": {
            "propose new idea": "The speaker introduces the concept of toxins as a factor affecting the system, which hasn't been discussed before.",
            "develop idea": "The speaker expands on the idea by detailing the effects of a fungal toxin on epithelial cells and microphages."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So how did you how did you find these toxins? Because you were doing proteomics and you found this instead of a protease? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the methodology used to find toxins, comparing it to proteomics and the finding of a protease."
        }
    },
    {
        "utterance": "Iliyan Iliev: No, it's a huge study. So we started differently. So we first looked at uh patients with IBD where we were looking for specific fungi. So we found actually fungi that are enriched in those specific patients and from there we wanted to see uh if there is any correlation with uh enrichment of those fungi and the disease. And then there wasn't. So we went patient by patient and isolated different strains of uh those fungi and then did genomics and number of different platforms in vitro and that's where actually all those strains, it was a lot of work. So a lot of strains basically split by their ability to damage epithelium or not and they're the same species. So from there we basically took over what is the reason and that's why we went for all the proteases but it wasn't that and then in the genome we found actually this fragment which is responsible for activation of toxin that is process extra cellularly. So so anyway and that toxin though is super potent. Uh and it's actually released in the patients and it correlates with patients that have severe disease, they care carry the strains that produce the toxin. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their research approach and findings, providing details about their study on fungi and IBD."
        }
    },
    {
        "utterance": "Dave Durgan: slightly in terms of uh the inflammatory response originating from the meninges and then migrating into the brain. Um as we've looked at stroke models more closely, it's not just inflammation in the parenchyma but uh it seems like a large portion of those immune cells are coming from from the meninges and uh it's one of these areas where there's fenestrated uh on the Venus side so it's one of these areas that are very open uh to potentially uh their metabolites or to uh endotoxins things like that coming from uh from the gut. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a concept related to inflammatory responses in stroke models, discussing the origin of immune cells and their potential impact on the brain."
        }
    },
    {
        "utterance": "Dave Durgan: And there there's just some really interesting observations there. For instance, if you get inflammation and upregulation of IGA in the gut, it also corresponds with increased IGA production uh in the dural layer. Um so it's kind of this coevolutionary idea that it's it's in the benefit of the organism to if something gets across the epithelial barrier to also be able to recognize that at the brain um and respond in a very rapid way, whether that be uh plasma cells which are migrate sensitized in the gut and then migrating to these these areas in the meninges that then have pretty free access to get across to the brain. So kind of an interesting idea. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on a concept by providing specific examples and explanations, building upon existing ideas.",
            "offer feedback": "The speaker provides an example and an idea that could be seen as offering feedback on the topic.",
            "supportive response": "The speaker is providing a positive evaluation or validation of an idea."
        }
    },
    {
        "utterance": "Iliyan Iliev: But what's the antigen there? That's very interesting. And I I looked at those studies. But what's the antigen in the brain that will activate the plasma cell to keep excreting those IGAs or it's a passive process. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the antigen in the brain that will activate the plasma cell to keep excreting those IGAs, indicating a question being asked."
        }
    },
    {
        "utterance": "Dave Durgan: Well, the I mean the antigens could be coming from either direction, either from there there's circulation to the meninges. and on the Venus side that's where it's highly fenestrated. So you can have antigens from gut entering circulation and then sensitizing these cells in the meninges or you can have like in the case of stroke or brain damage, you can have antigens coming from the parenchyma as well across the meninges and setting off the immune cascade there. ",
        "annotations": {
            "develop idea": "The speaker is building upon previous discussions by suggesting a possible mechanism for how antigens from the gut could influence the brain, specifically through circulation to the meninges.",
            "offer feedback": "The speaker is providing specific perspectives on the potential sources of antigens and their impact on the immune response in the meninges."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yes, all the migration of IGA plasma blast from the gut going far away, it's very hard to track. We worked a lot on IGA and uh I kind of limit the work actually to the gut because it was very hard to really. ",
        "annotations": {
            "identify gap": "The speaker explicitly mentions the difficulty in tracking the migration of IGA plasma blasts, indicating a gap in current knowledge or capability.",
            "signal expertise": "By stating 'We worked a lot on IGA', the speaker is signaling their expertise or experience in the area of IGA research."
        }
    },
    {
        "utterance": "Dave Durgan: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: because IGA plasma blasts are different and they produce uh you know the just monomeric IGA if you if you have antigen going actually systemic and and uh and uh priming them. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing knowledge about IGA plasma blasts, providing more details about their characteristics and behavior."
        }
    },
    {
        "utterance": "Iliyan Iliev: So that's where I don't know what what uh what is the way to track them from the gut to the brain. ",
        "annotations": {
            "ask question": "The speaker is requesting information on how to track IGA plasma blasts from the gut to the brain, seeking clarification or expertise from others."
        }
    },
    {
        "utterance": "Dave Durgan: Um all that I can say to that I guess is the evidence that that I'm familiar with is so in the same animal they've uh done B cell receptor sequencing. ",
        "annotations": {
            "offer feedback": "The speaker provides specific information about B cell receptor sequencing as evidence, which serves as feedback to the discussion."
        }
    },
    {
        "utterance": "Iliyan Iliev: Oh with BCRs, okay. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a point made, showing understanding."
        }
    },
    {
        "utterance": "Dave Durgan: in the in the gut as well as in these areas in the meninges and shown that there's uh very high similarity or cooccurrence of the same receptor uh in both sites that statistically shouldn't be occurring um unless these plasma cells were actually migrating uh from gut to to these meningial areas. ",
        "annotations": {
            "final answer": {
                "develop idea": "The speaker is expanding on previous ideas or discussions, providing more details about research findings."
            }
        }
    },
    {
        "utterance": "Dave Durgan: So kind of an interesting idea. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing a positive sentiment towards an idea previously discussed, indicating agreement or validation."
        }
    },
    {
        "utterance": "Faranak Fattahi: I have a unrelated question. Um so from the standpoint of developing models that would help the field, um where do you think are like do we have some good ideas around what factors could be triggering the leaky bear like the leaking barriers and we're just trying to drill down on the mechanisms of how that happens or are we in the phase where we're like we should be screening for a larger set of molecules or metabolites or factors that could be coming from the microbiome. I'm trying to think if we need some sort of scalable model in order to search for more of those or models that would help us like, you know, interrogate specific things mechanistically on a more complex level. Uh maybe the answer is both, so I'd love to hear from all of you about that. ",
        "annotations": {
            "ask question": "The speaker is explicitly asking for thoughts on developing models and factors that could trigger leaky barriers, seeking information from others.",
            "propose new idea": "The speaker suggests the possibility of needing scalable models or screening a larger set of molecules/metabolites, introducing a new perspective on approaching the problem."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Don't all speak at the same time. ",
        "annotations": {
            "Process management": "The speaker is managing the meeting flow by asking participants not to speak at the same time."
        }
    },
    {
        "utterance": "Tom Mansell: Well, if if we're talking about metabolites, you know, generally we think about metabolites as as organic molecules, right? But a lot of proteases um are are metal dependent, right? So are there bacteria that are I I know for example, um E coli Nissel is um heightens that niche defense because it has a tons of iron transporters. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of bacteria with specific characteristics, such as having a lot of iron transporters.",
            "develop idea": "The speaker is expanding on the previous discussion about metabolites and proteases, considering their characteristics and potential implications for bacterial behavior."
        }
    },
    {
        "utterance": "Tom Mansell: basically sucks up all of the iron. And so other organism which is limiting so other organisms are not allowed to use it. Um but zinc and calcium and other, you know, cat ions are often a part of these metallo or matrix metallo proteases. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about how bacteria compete for resources like iron and how certain cations are involved in metallo proteases, providing more detail and examples."
        }
    },
    {
        "utterance": "Tom Mansell: Um and so one like even lower than the sort of organic metabolite level is like what's the ion composition um there and is that something that could provide as as as Faranak said uh more mechanistic understanding. Um so things that are secreting siderophores, right? are which which grab and chelate uh ions out of the um out of whatever matrix they're in. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about metabolites by suggesting a focus on ion composition and siderophores.",
            "ask question": "The speaker is asking about the ion composition and its effects, seeking more information."
        }
    },
    {
        "utterance": "Tom Mansell: Um thoughts on that anybody? ",
        "annotations": {
            "Ask question": "The speaker is requesting thoughts or opinions from others, which can be considered a question.",
            "Encourage participation": "The speaker is inviting others to contribute their ideas or opinions."
        }
    },
    {
        "utterance": "Faranak Fattahi: No. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So are you are you only referring to iron or to any other inorganic molecules? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on a prior statement regarding inorganic molecules, specifically asking if the reference is only to iron or if it includes other inorganic molecules."
        }
    },
    {
        "utterance": "Tom Mansell: I was just using iron as an example because um uh you know, E Nissel has a bunch of these so therefore and that's how it promotes niche defense. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on his previous statement about iron and its role in niche defense, providing a specific example of how E. Nissel uses iron to promote niche defense."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So to go back to Faranak's question like what would be a model system to figure out if and how bacteria microbes impact let's just stick with the gut epithelial barrier. you know, barrier function in general. ",
        "annotations": {
            "ask question": "The speaker is asking for suggestions on model systems to study the impact of bacteria and microbes on the gut epithelial barrier.",
            "identify gap": "The utterance implies a gap in knowledge regarding suitable model systems for studying microbe-barrier interactions.",
            "clarify goal": "The speaker seeks to understand how microbes impact barrier function, specifically by asking about model systems."
        }
    },
    {
        "utterance": "Erin Longbrake: I mean it seems to me like this starts with in vitro experiments with iterative culture systems like you know you have bacteria, you mix bacteria, you you know and then you simplify. ",
        "annotations": {
            "final answer": {
                "propose new idea": "Erin introduces a new approach for studying the impact of bacteria on the gut epithelial barrier, suggesting in vitro experiments with iterative culture systems."
            }
        }
    },
    {
        "utterance": "Erin Longbrake: That gets a little more complicated because not all bacteria live nicely in culture systems. Um you could also do it with supernants and then try to fractionate the supernants from gut. Um but again, um this seems like an iterative screening process where you have a model system and you iteratively just screen. ",
        "annotations": {
            "offer feedback": "The speaker is suggesting alternative methodological approaches to studying the impact of bacteria on the gut epithelial barrier.",
            "develop idea": "The speaker is elaborating on the challenges of studying bacteria in culture systems and suggesting alternative approaches like using supernants."
        }
    },
    {
        "utterance": "Faranak Fattahi: Focus on it just. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: proteases, right? So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, uh well, some of them, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi: with the factors or you know the mechanisms are and how they affect the epithelial cells other tissue control rings. You could like imagine multiple layers of in vitro models. You can have a very simple model with just epithelium or like more complex models of gut organoids and then you can have the nerves being there or the immune cells being there and have validation layers then eventually translate all this to mice. ",
        "annotations": {
            "develop idea": "The speaker elaborates on a methodological approach for research."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I have not heard much and maybe you guys talked about it when I when I got kicked out about mucose and the mucosal, you know, membrane because that's important too. And that's a source of interaction with microbes. Any comments, thoughts? ",
        "annotations": {
            "ask question": "The speaker is explicitly seeking information or thoughts from others regarding the mucosal membrane and its interaction with microbes.",
            "encourage participation": "The speaker invites others to contribute their comments or thoughts, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Faranak Fattahi: I mean, would some of these same proteases be involved in mucosal disintegration or like are there ways that microbes could trigger higher production of mucus or is that like, you know, worse for their own survival? I'm not sure just like I don't really know much about the like microbe mucus production cycle if that's something there's much known about that or not. ",
        "annotations": {}
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's really important, I think. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing a positive evaluation of a previous contribution, indicating agreement and importance."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so they are they are mucinolytic bacteria and and uh are very good examples and you know like uh fungi that we study some of them are actually present in the mucus that's how we figure out actually that they're important for the barrier function. Uh so so uh we still try to figure out if they utilize the mucus uh as a source or they are there for other reasons but for the mucinolytic bacteria is figured out and the enzymes are isolated so that's uh that that's some cool science that has been done there. I I really liked you know the studies from uh uh. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas about mucinolytic bacteria and their role in barrier function.",
            "acknowledge contribution": "The speaker references unnamed studies, acknowledging the contributions of others in the field."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Who's left? ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by checking who's left to contribute or be acknowledged."
        }
    },
    {
        "utterance": "Iliyan Iliev: Gunnar Gunnar Hansen. He's in uh Sweden. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Do I ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: I went to one meeting that was very boring and that talk shine and from there it opened another talk. ",
        "annotations": {
            "express humor": "The speaker makes a joke about a boring meeting and a talk that led to another talk, attempting to be humorous."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Do any of you know the name or maybe you can put it in the chat? ",
        "annotations": {
            "code name": "ask question",
            "explanation": "The speaker is requesting information from the group about a name they are trying to recall."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: He's uh I think you spell it like that or something here let me see. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So one of the things that got brought up at last year's dialogue meeting was we had there was a bunch of like um engineers who were making things that you ate that went and sampled your gut at multiple locations on all the way down. I almost think that some of thing like this if you could if you could um have that kind of a technological probe that samples mucosal if you will or kind of adherent bacteria um that then you could do sequencing on and kind of target your in vitro screening models to the bugs that you now know are stuck to the mucosa maybe that would be a way to narrow things down a little bit from the entire gut microbiome. I am not a chemist or an engineer in any way but that was something that was brought up a bunch last year. ",
        "annotations": {
            "develop idea": "Erin Longbrake is expanding on an idea from a previous meeting, suggesting using a technological probe to sample mucosal bacteria.",
            "offer feedback": "She is suggesting a method for targeting specific bacteria for in vitro screening models.",
            "signal expertise": "Erin Longbrake states she is not a chemist or an engineer, signaling her lack of expertise in certain areas."
        }
    },
    {
        "utterance": "Iliyan Iliev: No, it's uh it's actually exists that how we found the mucosa associated fungi. So basically all the patients that come for colonoscopy, they go on cleansing so they're clean uh relatively clean and then you go with a scope and you can actually go against the wall and wash from there and take that part and that's where we did the sequencing and that's how we found what's associated with the mucosa but uh in humans it's very hard otherwise. If you go with a probe it's not going to go in the mucosa and sample clean because it will go goes after that in the fecal material. But in mice you can do a lot of cool stuff though. Uh but for humans it's kind of very tricky. We thought about it about two to three years before getting to the right procedure. ",
        "annotations": {
            "develop idea": "The speaker is explaining a specific research method they used to find mucosa-associated fungi, elaborating on the process.",
            "signal expertise": "The speaker shares specific knowledge about the research method, indicating his expertise in the area.",
            "identify gap": "The speaker identifies a challenge in researching mucosa-associated fungi in humans, noting the difficulty in obtaining clean samples."
        }
    },
    {
        "utterance": "Tom Mansell: that there are on a carbohydrate level, there are some carbohydrate substrates that can be modified um. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: azide groups. So if you have a particular, for example, an O glycan that would be a substrate for a mucinophilic bacteria. Um it's possible that you could synthesize and one of those moieties with a click um substrate on it. So the azide group which enables click chemistry or ligation which would you could then click on a fluorescent probe uh too, right? So um you could those bacteria that are utilizing these things might break it down and then incorporate that into their um you know, proteoglycan. ",
        "annotations": {
            "propose new idea": "The speaker introduces a novel approach using azide groups and click chemistry to study bacterial interactions with substrates.",
            "develop idea": "The speaker elaborates on the proposed method, including the use of clickable substrates and fluorescent probes."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah is there anything like on click chemistry in uh you know, you cannot do that because you cannot express it in the in whole cells. But it will be very cool if you can develop a click chemistry that actually the human cell is producing half of of the azide, right? And then you add the probe. That will be very cool. ",
        "annotations": {
            "propose new idea": "The speaker suggests developing a click chemistry method where human cells produce half of the azide.",
            "develop idea": "The speaker elaborates on the idea of using click chemistry in human cells.",
            "ask question": "The speaker asks if there is anything like click chemistry that can be expressed in whole cells."
        }
    },
    {
        "utterance": "Tom Mansell: Oh, that's that chemistry sounds pretty hard to do in vivo. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: It's very hard. Yeah, yeah, yeah. That but that's that's the dream actually to do it. Otherwise with the substrate it's very cool as well but uh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Right. ",
        "annotations": {
            "Supportive response": "This code applies because the utterance 'Right.' explicitly expresses agreement with a prior statement made by another group member."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah. ",
        "annotations": {
            "None": "The utterance is a simple acknowledgment without any specific content that matches the provided codes."
        }
    },
    {
        "utterance": "Pamela Chang: Sorry, so I was a PhD student in Carolyn's lab and that was part of my PhD thesis. So actually since I left the lab uh the number of studies have come out from other groups that have been able to do that in vivo labeling in in in a mouse. Um and in some cases they can even do the click chemistry in vivo too. Uh if you're interested I can send you send you some uh some of those papers but but yeah, I'm I sorry I didn't mention I'm trained as a chemist my PhD and then I went to immunology. ",
        "annotations": {
            "develop idea": "The speaker is expanding on their previous experience and work done by others in the field.",
            "signal expertise": "The speaker is explicitly stating her background and qualifications as a chemist and immunologist."
        }
    },
    {
        "utterance": "Tom Mansell: I'd be really interested in that um for sure. ",
        "annotations": {
            "supportive response": "Tom Mansell is expressing interest and a positive sentiment towards Pamela Chang's offer to send papers, which is a form of supportive response."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So we have about another 15 minutes and then it might be a good idea to look at um to maybe have Erin share her screen so we can summarize highlights and see what we're going to report. Um so I'm I'm I'm I'm happy to let you know in like 10 or 15 minutes but I just wanted to bring to your attention that maybe um if there's something you really wanted to say and you haven't brought it up, maybe this is a good time. ",
        "annotations": {
            "process management": "Rosa Krajmalnik-Brown is managing the meeting flow by indicating the time left for discussion and planning for summarizing highlights.",
            "encourage participation": "Rosa Krajmalnik-Brown is encouraging participation by inviting anyone who has something important to share to do so before the summary."
        }
    },
    {
        "utterance": "Faranak Fattahi: I have no specific thoughts, but I do have a question. I I wondered if Melanie could tell us a little bit more about the assays you do to measure epithelial barrier. We talked about um fluxing chambers and um so how how high throughput are they and like can you like, you know, test 100 things or is it like only a matter of a few things that you can evaluate in them? ",
        "annotations": {
            "ask question": "The speaker is requesting information, clarification, or expertise from another team member on a prior statement or idea proposed."
        }
    },
    {
        "utterance": "Melanie Gareau: Sure. Um so chambers are great at getting lots of information on not so many samples. Um so they're not very high throughput. We have eight right now um to do a fitC assay, it's a two hour assay, so you can only do eight times two, maybe three in a day, so it's low throughput. ",
        "annotations": {
            "signal expertise": "Melanie is sharing her expertise on the assay process.",
            "identify gap": "She identifies a limitation of the assay, which is its low throughput.",
            "process management": "The utterance discusses the management of assays, specifically their limitations and how they are conducted."
        }
    },
    {
        "utterance": "Melanie Gareau: Um but you get a lot of information um so we can really get at the pathway whether it's transcellular, um uh paracellular, um when you modify the chambers you can actually get at whether enteric nerves are contributing to it because they're still intact in there. Um so it's they're really powerful but they're very low throughput. ",
        "annotations": {
            "Develop idea": "Melanie is elaborating on the capabilities and applications of using chambers to study intestinal physiology, including understanding pathways and the role of enteric nerves.",
            "Signal expertise": "Melanie is explicitly stating her experience and knowledge with the chambers, their modification, and their applications in studying intestinal physiology."
        }
    },
    {
        "utterance": "Faranak Fattahi: Um so that's one of the big problems. ",
        "annotations": {
            "supportive response": "The speaker is acknowledging and agreeing with the previous discussion about a challenge."
        }
    },
    {
        "utterance": "Melanie Gareau: We can put organoids on them so we don't we haven't done it yet, but I know that you can so you can put inserts in in there. ",
        "annotations": {
            "propose new idea": "Melanie suggests using organoids on the equipment, introducing a new approach.",
            "develop idea": "She expands on the existing idea of using inserts by suggesting organoids could also be applied."
        }
    },
    {
        "utterance": "Melanie Gareau: Um there so you you can get more information than for example um TER for uh Kiko tubes or something like that. Um so so and we can also do in vitro stimulation. So you can you can put molecules in there, watch them transport across or see how they interact and generate or change ion transport or permeability. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the capabilities of using chambers for studying epithelial barriers, including in vitro stimulation.",
            "Signal expertise": "The speaker is demonstrating her expertise in the field by discussing specific methods and their applications."
        }
    },
    {
        "utterance": "Melanie Gareau: So we've done that as well. Um it it's the throughput problem. So you really need to know what you're you have to narrow it down um before you set it up. ",
        "annotations": {
            "develop idea": "Melanie is expanding on existing ideas by discussing the practical limitations of assays for measuring epithelial barrier function.",
            "supportive response": "Melanie is providing additional information to support the discussion on experimental design and assay limitations."
        }
    },
    {
        "utterance": "Faranak Fattahi: Are there like markers? I'm thinking if there are if you have like a section of the epithelium or just like an epithelial monolayer culture, are there proxies or markers that correlate with epithelial integrity that you could use for a higher throughput and maybe image-based analysis or some other indirect way of correlating that with barrier integrity to then first cast the wide net and then narrow things down for these more sophisticated measurements. ",
        "annotations": {
            "ask question": "The speaker is seeking information on whether there are markers that correlate with epithelial integrity for use in higher throughput analysis.",
            "develop idea": "The utterance builds upon the existing discussion about studying epithelial barrier integrity by inquiring about potential markers for this purpose."
        }
    },
    {
        "utterance": "Melanie Gareau: Not a reliable one that I could think of. Um I'd have to maybe go back and look a little bit more closely, but to my knowledge there isn't one really reliable factor. There's a few that have kind of come up and then we're kind of disregarded. Um I think there's more a lot of movement towards uh co-culture systems with um more engineering involved where you have small wells that are separating cells um to kind of create gut brain models that way. So I that's not something that I know much about, but that's certainly where people are going with um collaborating epithelial physiologist collaborating with um engineers and things like that. So there I know there's a lot of people that are creating uh in vitro compartmentalized systems where you can compare those things, those would be higher throughput. ",
        "annotations": {
            "identify gap": "Melanie Gareau explicitly states a lack of knowledge about reliable factors for epithelial integrity.",
            "supportive response": "She provides information that contributes to the discussion.",
            "encourage participation": "By discussing current research trends, she invites others to engage with these topics."
        }
    },
    {
        "utterance": "Tom Mansell: Hey, would you mind putting the name of this uh device in the chat? I'm going to so I know how to spell it. ",
        "annotations": {
            "ask question": "Tom Mansell is requesting information about the name of a device mentioned in the conversation."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I caught chambers but not. ",
        "annotations": {
            "acknowledge contribution": "Erin Longbrake acknowledges understanding or receipt of information about 'chambers' but indicates uncertainty or lack of understanding about something else."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, yeah. Okay, great. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement or validation with a previous statement, indicating a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So what I'm hearing from you Melanie is that um these are great to test specific hypothesis, which is what you do with a lower throughput system. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing what has been previously discussed by Melanie about the use of certain experimental approaches for testing specific hypotheses.",
            "supportive response": "The speaker is also showing agreement or validation of Melanie's point about the experimental approaches being suitable for testing specific hypotheses."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You know, I think people that think about higher throughput system is more to do stuff that I would say it's maybe more exploratory. Um which is great, you know, to generate hypothesis, but it sounds like your systems are good to test specific hypothesis. Is that am I hearing that right? ",
        "annotations": {
            "Ask question": "The speaker seeks confirmation or clarification from the group.",
            "Summarize conversation": "The utterance summarizes the understanding of previous discussions regarding experimental systems.",
            "Process management": "It manages the discussion flow by ensuring clarity and confirmation of understanding."
        }
    },
    {
        "utterance": "Melanie Gareau: Yes. ",
        "annotations": {
            "acknowledge contribution": "Melanie Gareau is acknowledging Rosa Krajmalnik-Brown's interpretation.",
            "supportive response": "Melanie Gareau is showing agreement with Rosa Krajmalnik-Brown."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You know, do you want to share Erin? I hope you can share so we can all make sure that um your contributions are all there. ",
        "annotations": {
            "process management": "The speaker is facilitating the group's work process by asking Erin to share her contributions."
        }
    },
    {
        "utterance": "Erin Longbrake: Um it looks like I can give me one second to find the right window. Okay, here we go. ",
        "annotations": {
            "process management": "Erin is managing the meeting flow by preparing to share her screen."
        }
    },
    {
        "utterance": "Erin Longbrake: Erin Longbrake (Yale) has started screen sharing ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by initiating screen sharing."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Is this how they want us to share it? ",
        "annotations": {
            "process management": "This code applies because the speaker is inquiring about the correct procedure for sharing documents or screens during the meeting, which directly relates to managing the meeting's flow and organizational activities."
        }
    },
    {
        "utterance": "Erin Longbrake: Because last year they actually had a a slide, a PowerPoint slide. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi: Right, I think we need to copy this over to the PowerPoint deck. I think it's also in the same Google Drive. ",
        "annotations": {
            "process management": "The speaker is suggesting to copy information to a PowerPoint deck and checking if it's already in a Google Drive, which relates to managing meeting materials."
        }
    },
    {
        "utterance": "Erin Longbrake: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So that's something that maybe we can do. ",
        "annotations": {
            "supportive response": "Erin is expressing agreement and willingness to consider an idea previously discussed, showing a positive and supportive attitude towards the group's efforts."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, this one. ",
        "annotations": {
            "acknowledge contribution": "Erin Longbrake acknowledges a previous point or suggestion made by someone else, showing recognition without adding new content."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, that one. ",
        "annotations": {
            "acknowledge contribution": "Erin Longbrake acknowledges something previously mentioned or shown."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: idea though is to have just a couple points. We wanted to still our discussion to. ",
        "annotations": {
            "process management": "The speaker is attempting to manage the meeting discussion by suggesting to focus on just a couple of points."
        }
    },
    {
        "utterance": "Erin Longbrake: Points that are shareable. ",
        "annotations": {
            "summarize conversation": "Erin is suggesting points that are shareable, implying a summary or key takeaways from the discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, exactly. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement with a previous statement, showing support and validation without adding new content."
        }
    },
    {
        "utterance": "Erin Longbrake: All right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: We can talk about if they're linked or correlated, but that's fine. ",
        "annotations": {
            "supportive response": "Erin is expressing willingness to discuss the topic, indicating a positive and cooperative attitude towards the conversation."
        }
    },
    {
        "utterance": "Erin Longbrake: Okay, so there was a fair amount of discussion about the various pieces of things that could be impactful and direct versus indirect effects of gut microbes, soluble metabolites, proteases, effects on immune cells and then subsequent immune cell effects on so I think that was one common theme. ",
        "annotations": {
            "summarize conversation": "Erin Longbrake is summarizing the conversation, highlighting the discussion on direct and indirect effects of gut microbes, soluble metabolites, proteases, and their impacts on immune cells."
        }
    },
    {
        "utterance": "Erin Longbrake: Um. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: There was some talk about two different barrier functions, the gut epithelial barrier and the blood brain barrier is potentially both being important to understand separately and the likelihood of multi-hit hypothesis um being necessary to open them all. Um Tom brought up some interesting points about molecular structures and the how the tight junctions were functioning and whether bacteria could change the composition of tight junctions um or add or subtract some key component of the epithelial barrier. ",
        "annotations": {
            "summarize conversation": "The speaker summarizes previous discussions about barrier functions and molecular structures."
        }
    },
    {
        "utterance": "Erin Longbrake: And then the I discussion. Yeah, inorganic chemistry I would call it. But yes, you can call it ion discussion. Yeah. And then the discussion about model systems and we didn't have a good answer for a high throughput screening system, but it seemed like that was what would be needed to tease it out and break it apart was a first a high throughput screening system. ",
        "annotations": {
            "summarize conversation": "Erin Longbrake summarizes previous discussions about model systems and the need for high-throughput screening systems."
        }
    },
    {
        "utterance": "Erin Longbrake: And then iteratively more complicated methods. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Um and we had talked about engineering models to in human sample bugs from different anatomic regions or locations within the lumen versus the mucosa and then in mice using different parts of the intestinal tract in the using chamber model system to study specific effects, but it being necessary to do a fair amount of preliminary high throughput work to get your hypothesis to study in the more detailed model system. I don't know. ",
        "annotations": {
            "develop idea": "Expanding on previous discussions about models and methodologies for studying the effects of bugs from different anatomic regions.",
            "identify gap": "Mentioning the necessity of preliminary high-throughput work, indicating a current limitation.",
            "clarify goal": "Explaining the purpose of using engineering models and high-throughput work for hypothesis testing."
        }
    },
    {
        "utterance": "Erin Longbrake: That's what I'm pulling out. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Thanks. ",
        "annotations": {
            "Acknowledge contribution": "The speaker is verbally recognizing another group member's input or assistance."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's good. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement or validation of the previous discussion or statement."
        }
    },
    {
        "utterance": "Erin Longbrake: I just have to recapitulate it again. Hold on. ",
        "annotations": {
            "summarize conversation": "Erin is seeking to recapitulate or summarize previous discussion points.",
            "process management": "Erin is managing the discussion flow by asking to pause and summarize."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: interactive, please speak up also if you see something missing. ",
        "annotations": {
            "encourage participation": "The speaker invites group members to contribute their thoughts if they notice something missing, encouraging active participation in the discussion."
        }
    },
    {
        "utterance": "Erin Longbrake: Yes, please. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement and willingness to do something requested."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, I'm eating as you write because I'm going to have to run to teach right after we close. So if I don't eat now, I won't eat in like three hours. ",
        "annotations": {
            "express humor": "The speaker makes a joke about eating because she won't have time to eat in three hours.",
            "process management": "The speaker is managing the meeting flow by indicating she needs to leave soon to teach."
        }
    },
    {
        "utterance": "Erin Longbrake: Of course. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And and you're you're writing there need for high throughput screening, but maybe we can also add a bullet point of there are some lower throughput screening methods that might be good to test specific hypothesis, but we need to get there. We need to know which specific hypothesis. We want to be testing. What do you guys think? ",
        "annotations": {
            "Develop idea": "Building on the idea of high throughput screening by suggesting lower throughput methods for specific hypotheses.",
            "Ask question": "Requesting opinions from the group on the approach to screening methods.",
            "Process management": "Guiding the discussion flow and objectives."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Feel free to correct it or add something else. I'm just trying to get other people help Erin. ",
        "annotations": {
            "encourage participation": "Rosa invites others to contribute to the discussion or help Erin."
        }
    },
    {
        "utterance": "Melanie Gareau: Erin, it's oozing with ing, not AR, I just noticed. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance based on the strict definitions provided."
        }
    },
    {
        "utterance": "Erin Longbrake: Okay, thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Has anybody here been gotten successfully funded by the bylog? ",
        "annotations": {
            "ask question": "Tom Mansell is requesting information on if anyone has been successfully funded by the bylog."
        }
    },
    {
        "utterance": "Erin Longbrake: I didn't last year. ",
        "annotations": {
            "acknowledge contribution": "Sharing personal experience in response to a question."
        }
    },
    {
        "utterance": "Tom Mansell: we didn't either. ",
        "annotations": {
            "supportive response": "The speaker is expressing a similar experience, providing a form of support or validation to the previous speaker."
        }
    },
    {
        "utterance": "Tom Mansell: I I have a grant. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I know I know someone at ASU that got funded last year by the way. Habishek, I don't know if you met him last year. ",
        "annotations": {
            "ask question": "Rosa is inquiring if anyone met Habishek, which is a direct question seeking information.",
            "encourage participation": "Rosa is directly asking if someone met Habishek, which invites a response."
        }
    },
    {
        "utterance": "Dave Durgan: partner on that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Okay, there you go. ",
        "annotations": {
            "Supportive Response": "Tom Mansell is acknowledging and validating the information shared by Rosa Krajmalnik-Brown about someone at ASU getting funded."
        }
    },
    {
        "utterance": "Tom Mansell: I'm just thinking that for their purposes, like so, you would think that, okay, so if you go to NIH with this idea, right? If you're talking about high throughput high throughput screens, immediately a reviewer says this is a fishing expedition. This is hypothesis generating, go somewhere else, right? Do you think that these guys are keen to fund that kind of thing or like hypothesis generation, which will be too risky for NIH, or do you think that they're more translationally focused on that. ",
        "annotations": {
            "ask question": "Tom is questioning the approach of funding agencies to high-throughput screens and hypothesis generation, seeking clarification on their priorities."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: There's a on the high risk high yield, I thought. ",
        "annotations": {
            "None": "The utterance is a casual comment that does not explicitly fit into any of the provided codes, as it simply references prior information about a 'high risk high yield' funding mechanism."
        }
    },
    {
        "utterance": "Tom Mansell: High risk high yield, right? So it's. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement or validation with a previous statement about high risk, high yield research approaches."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah. So I I confess I was invited to be part of the review panel last year, but I wasn't. So I wish I had been there so I could give you an answer of like what the panel was actually looking for. We didn't get a lot of feedback either, so that was. The and I I can you can provide that on your surveys as a comment that it would be helpful to get some feedback on your proposal so they know what you're they're looking for, right? And I can provide that too since I heard it from you, but my guess is that the the idea of this is to get funding that NIH wouldn't fund funded, you know, or get you started. ",
        "annotations": {
            "process management": "The speaker discusses the process of reviewing proposals and providing feedback, indicating an interest in managing how the funding process works.",
            "offer feedback": "The speaker explicitly mentions providing feedback on proposals and suggests that it would be helpful for applicants to know what reviewers are looking for."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, it's it's really crazy. I I had like two grants not discussed there. It's a cell paper. It's just ridiculous. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it primarily expresses frustration or disappointment without directly engaging in scientific discussion or collaboration."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Anyway, so. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So so those are the mechanisms here, yeah. one one comment that I want to make especially to junior faculty is that not funded by NIH does not mean that it's not good research and it doesn't mean that it's not promising research. NIH NIH chose not to fund the production of insulin through genetic engineering the way it's done, you know, because it it was too risky to blah blah blah. So the the investigator that proposed that got completely rejected and that's the way that insulin is produced in, you know, for everyone nowadays. So there are many great ideas that don't go through NIH and I'm not saying don't go to NIH and I'm not saying, you know, don't try, but I I what I'm saying is that if you know it's a good idea, pursue it through other ways or pursue getting preliminary data so you can show that to NIH. That's that's my advice here, you know, my mentoring advice. ",
        "annotations": {
            "signal expertise": "The speaker is sharing her expertise and experience, particularly in the context of funding and research.",
            "supportive response": "The speaker is providing encouragement and support to junior faculty.",
            "offer feedback": "The speaker is providing guidance and advice."
        }
    },
    {
        "utterance": "Pamela Chang: Are there other, sorry, this is getting a little off topic, but are there other foundations that would be interested in funding gut microbiome research because I had a similar experience with NIH. I don't know if anyone else found alternatives. I mean, aside fromlog. ",
        "annotations": {
            "code name": "ask question",
            "explanation": "Requesting information or experiences from other group members regarding funding sources for gut microbiome research."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I I would say, um, my with my knowledge and my experience because there might be others, they're more like disease specific. So I've gotten I've gotten funding from Autism Research Institute and Autism Speaks. They're more to the disorder that you're targeting. And and and I also want to mention because I'm a reviewer at NIH that one of the challenges at NIH is that right now microbiome is everywhere. So what they do is you send a proposal that has some microbiome component, they send it to a panel that is investigating, I'm going to put aging as an example, okay? So aging and the microbiome. So they send it to an aging panel where no one there knows about the microbiome, but they call someone like Rosie to be the microbiome expert. And no matter how much Rosie likes that proposal, there's other reviewers that don't maybe don't appreciate the value of the microbiome. So unless Rosie is super outspoken and super defense that proposal and super able to articulate the importance of the microbiome there, the proposal will not get funded. ",
        "annotations": {
            "signal expertise": "Rosa Krajmalnik-Brown mentions her role as a reviewer at NIH, signaling her expertise in the field.",
            "identify gap": "Rosa points out a challenge in the NIH review process for microbiome research, highlighting a gap in expertise among reviewers.",
            "offer feedback": "Rosa provides insights and advice on how to navigate the funding landscape, especially for microbiome research."
        }
    },
    {
        "utterance": "Iliyan Iliev: And especially if you end up in a study section when, you know, they're already established for a long time, if it goes to brain study section, you come with immunologist, what are you talking about? We study circuits here, you're dead. So. ",
        "annotations": {
            "Critical response": "The speaker is providing a negative evaluation of the situation (being an immunologist in a brain study section), implying criticism of the system."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And and I'm telling you honestly because I've been called to so many of these panels in the last two, three, four years that I've tried very hard to find the value on the microbiome, especially when it's good work and to try to defend it, but it doesn't always work, you know? So, um, yeah. And so one thing that I see in the microbiome world that it's really important is that we we raise each other, especially with good science, you know, and we defend each other because that's really important. Uh, but of course that you do good science because otherwise nothing's going to proceed, but I I'm sure you guys are here because you do good science, otherwise you wouldn't even have been invited. ",
        "annotations": {
            "offer feedback": "Rosa provides her perspective and advice on navigating grant reviews, especially for microbiome research.",
            "clarify goal": "Rosa discusses the importance of good science and defending it, reflecting on the goals of scientific research."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, I mean the institution I'm right now, they're very supportive to that one time it will fly, but I was in another institution and I brought a grant that just gave like 5% or something and they asked me to find another 45% to pay to the institution. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, so it depends on the institution as well, yeah. ",
        "annotations": {
            "Supportive response": "Iliyan Iliev is providing a supportive comment by highlighting the significance of institutional support.",
            "Develop idea": "Iliyan Iliev is building upon a previous discussion about the challenges of securing funding and the role of institutions in supporting research."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You have the can, the can then move iteratively or you want you want it there. Can. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Are you guys happy with our report slide just to. ",
        "annotations": {
            "encourage participation": "Erin is inviting others to contribute their opinions or feedback on the report slide."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Sorry, Erin. ",
        "annotations": {
            "None": "The utterance is a simple apology and does not explicitly fit into any of the provided codes."
        }
    },
    {
        "utterance": "Erin Longbrake: No, no, no. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, amazing. Thanks a lot for doing that. ",
        "annotations": {
            "acknowledge contribution": "Iliyan Iliev verbally recognizes someone's input.",
            "supportive response": "The utterance expresses a positive evaluation."
        }
    },
    {
        "utterance": "Erin Longbrake: I'm going to go back to that for two minutes to make sure this isn't just me making stuff up. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Some institutes are more open. Some institutes will say like, you know, as long as you're doing good work and the money eventually comes in anyhow, right? Because that money is coming in for me to pay postdocs and for me to pay supplies and it has to come into the institution. You're absolutely right and I did it as a full professor. I don't know that this works for an assistant professor. Like I agree with you, you know? ",
        "annotations": {
            "signal expertise": "The speaker shares her experience as a full professor and provides perspective on funding.",
            "supportive response": "The tone is supportive and reflective, sharing experience.",
            "offer feedback": "The speaker provides her experience as feedback on the challenges faced by researchers."
        }
    },
    {
        "utterance": "Iliyan Iliev: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah, I mean the institution I'm right now, they're very supportive to that one time it will fly, but I was in another institution and I brought a grant that just gave like 5% or something and they asked me to find another 45% to pay to the institution. So so yeah, so it depends on the institution as well, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Where do you want it? You want it over there? ",
        "annotations": {
            "process management": "Erin Longbrake is managing the flow of information or materials within the meeting, specifically asking about the preferred location or method of sharing content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I don't know. I'm asking you if you wanted if if it was there on purpose. ",
        "annotations": {
            "ask question": "The speaker is requesting clarification on whether something was done intentionally, which is a direct question seeking information."
        }
    },
    {
        "utterance": "Erin Longbrake: It was supposed to be a bullet point under the one above, but it didn't format the way I thought it was going to. ",
        "annotations": {
            "process management": "The speaker is discussing a minor issue related to the formatting of a document or presentation, which relates to managing the collaborative process of creating a summary."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Oh, okay. Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: Is there anything additionally that I just big talk picks that I neglected to put on here? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on whether there are additional points to consider regarding the 'big talk picks' she has noted."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think um we mentioned fun size at some point and I don't I don't see it anywhere. I don't know if we want to call it out or not. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous mention of 'fun size'.",
            "ask question": "The speaker is asking for opinions on what to do with 'fun size'.",
            "process management": "The speaker is managing the discussion flow by tracking topics."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, there you go. Thank you. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input.",
            "supportive response": "The speaker expresses agreement, validation, or positive evaluation for other group members' contributions."
        }
    },
    {
        "utterance": "Erin Longbrake: All right. If you guys are happy with that, we can go back to the funding discussion, which is probably more high yield anyway. ",
        "annotations": {
            "process management": "Erin is managing the meeting flow by suggesting a shift in topics to discuss funding, implying it's a more important or productive use of their time."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Are you guys okay with that? Are you all okay with that? ",
        "annotations": {
            "process management": "Seeking agreement or confirmation from the group on a previous statement or proposal to manage the discussion flow."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I'm sorry, I didn't mean to divert the I was just trying to answer and help Tom. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: No, it was a high yield discussion and one that's definitely valuable. I just wanted to before we got dumped out, make sure that I was appropriately group centered on what I was reporting back. ",
        "annotations": {
            "Supportive response": "Erin expresses agreement and a positive evaluation of the discussion's value.",
            "Acknowledge contribution": "Erin acknowledges the discussion and her role in reporting back, recognizing the group's input or previous discussion."
        }
    },
    {
        "utterance": "Erin Longbrake: Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: NIH is really difficult. I just um yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: They don't like funding anything that's risky and there's a bias towards hypothesis. I I I don't fully buy into this like has to be hypothesis generated research. There's so much that we don't know you have to do observations before you can generate a hypothesis. So who's going to fund the observations? ",
        "annotations": {
            "ask question": "She asks a question about who funds observations.",
            "critical response": "She questions the bias towards funding hypothesis-generated research over observational research."
        }
    },
    {
        "utterance": "Faranak Fattahi: Startup package. ",
        "annotations": {
            "propose new idea": "The speaker is introducing an alternative source of funding, which is a new idea in the context of the discussion about funding research."
        }
    },
    {
        "utterance": "Erin Longbrake: Yeah, I mean it just seems it seems ridiculous. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: And and barrier inducing. So I don't know. There seems at least in my institution, there's a fair amount of um snobbery when it comes to being NIH funded versus not NIH funded. And I have a fair amount of pharma funding right now, which is good for me, but doesn't have the same cachet for promotion and tenure or whatever. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it primarily involves sharing an observation about funding and its implications on professional standing rather than engaging in the specific interactive processes listed."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's the thing that for promotion and tenure if you have an R01, it speaks volumes. ",
        "annotations": {
            "process management": "The speaker is discussing how having an R01 grant impacts career advancement in academia, specifically for promotion and tenure."
        }
    },
    {
        "utterance": "Tom Mansell: Maybe shouldn't. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: We're about we're about to be kicked out. I think Dave wanted to say something before we get kicked out. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow and time, ensuring that all participants have a chance to contribute before the meeting ends."
        }
    },
    {
        "utterance": "Tom Mansell: No, this has been great. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah, that was a great discussion. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and a positive evaluation of the discussion."
        }
    },
    {
        "utterance": "Iliyan Iliev: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah, thank you all. Thank you Aaron for putting the slides together. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes and thanks others for their contributions, specifically thanking Aaron for putting the slides together."
        }
    },
    {
        "utterance": "Unidentified Speaker: Thanks for reporting. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, thank you, Erin. ",
        "annotations": {
            "acknowledge contribution": "Tom Mansell verbally recognizes Erin Longbrake's input."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you. I'm sorry I got kicked out in the middle. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: You were you were back fast. It was good. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive sentiment and acknowledging someone's return in a meeting, showing agreement and validation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Um on the NIH, keep on pursuing it and talk to program directors. That's my advice because I I actually have two R1s funded and it wouldn't have happened if I hadn't talked to program directors and pursuing it and keep keep on trying, make it better, talk to program directors. That's my advice. ",
        "annotations": {
            "signal expertise": "The speaker shares her personal experience of securing two R01 grants and offers advice based on this experience.",
            "offer feedback": "The speaker provides advice on how to successfully secure NIH funding, based on her own experience.",
            "clarify goal": "The speaker aims to help others by sharing her strategy for securing NIH funding."
        }
    },
    {
        "utterance": "Tom Mansell: All right, thanks everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Thanks. ",
        "annotations": {
            "supportive response": "The speaker is expressing gratitude, which is a positive evaluation of the discussion or contribution."
        }
    },
    {
        "utterance": "Richard Wiener: Welcome back everyone. Uh is there anyone still working to get their notes into the PowerPoint? ",
        "annotations": {
            "process management": "Managing meeting flow by checking if anyone is still working on getting their notes into the PowerPoint."
        }
    },
    {
        "utterance": "Stephanie Cologna: I think our team could use like one more minute. ",
        "annotations": {
            "process management": "This code applies because the speaker is requesting more time for her team, which is a direct example of managing meeting flow and time."
        }
    },
    {
        "utterance": "Richard Wiener: All right, we'll give one more minute. We'll what we'll do for the report out is we'll just go to each room and ask the ",
        "annotations": {
            "process management": "Richard Wiener is managing the meeting flow by allocating more time and outlining the procedure for the report-out."
        }
    }
]